Sign In
Search Icon
Menu Icon

COVID-19 Therapeutics: Resources for Health Care Professionals and Public Health Officials

COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have mild to moderate COVID-19 symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on health care facilities, and even save lives.

At this time, Veklury (remdesivir) and Paxlovid (nirmatrelvir co-packaged with ritonavir) for adults (ages 18 and older) are approved therapeutics. Paxlovid for pediatric patients (ages 12-17) and Lagevrio are available under the U.S. Food and Drug Administration’s Emergency Use Authorization.

HHS/ASPR purchased supplies of COVID-19 therapeutic products for outpatient use. As these products transition to commercial market, HHS is working with state and territorial health departments as well as national health care and medical organizations and associations to maximize access to COVID-19 treatments.

On November 1, 2023, Lagevrio and Paxlovid became commercially available. To learn more about continuing HHS distribution timelines of HHS-procured inventory, please see Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.

Featured Resources

Outpatient COVID-19 Therapeutics

Oral Antiviral. Paxlovid (nirmatrelvir co-packaged with ritonavir). Federally Distributed. Learn More.  
Oral Antiviral. Lagevrio (molnupiravir). Federally Distributed. Learn More. 
IV Antiviral. Veklury (remdesivir). Commercially Available. Learn More. 

Previously Available COVID-19 Therapeutic Products

The products listed below are not currently authorized in the U.S because they are not expected to be effective against the currently circulating SARS-CoV-2 variants. Providers with non-expired inventory of these products are encouraged to retain them, as they have the potential to treat future variants more effectively.

Increasing Access to COVID-19 Therapeutics